Epilepsy-intellectual disability in females

Last updated
Epilepsy-intellectual disability in females
Other namesEIEE9, EFMR, GEF+ syndrome, epilepsy-intellectual disability in females, [1] Juberg-Hellman syndrome [2] [3] epilepsy limited to females with intellectual disability (EFID) [1]

Epilepsy-intellectual disability in females also known as PCDH19 gene-related epilepsy or epileptic encephalopathy, early infantile, 9 (EIEE9), is a rare type of epilepsy that affects predominately females and is characterized by clusters of brief seizures, which start in infancy or early childhood, and is occasionally accompanied by varying degrees of cognitive impairment. [4] [5] [6] [7] The striking pattern of onset seizures at a young age, genetic testing and laboratory results, potential developmental delays or developmental regression and associated disorders, eases diagnosis.

Contents

The National Institutes of Health Office and Rare Disease Research characterizes PCDH19 gene-related epilepsy as a rare disorder. [8] Although formal epidemiologic data is not available, results from diagnostic screenings indicate that approximately 1 out of 10 girls who have seizure onset before five years of age may have PCDH19 mutations. [9] [10] [11]

Signs and symptoms

PCDH19 gene-related epilepsy is a highly variable and rare epileptic syndrome, characterized by the early-onset of seizure clusters, with a range of 4 – 60 months, and an average onset at 12.9 months. [4] [5] [6] [7] Other aspects, such as varying degrees of cognitive impairment and behavioral and psychiatric problems, are also common, but are not essential for diagnosis of PCDH19 gene-related epilepsy. [4] [5] [6] [7] [12] [13] [14] [15] [16] [ excessive citations ]

PCDH19 gene-related epilepsy shares several clinical features with other early-onset epileptic encephalopathies, such as Dravet syndrome, generalized epilepsy with febrile seizures plus (GEFS+), FIRES (febrile infection–related epilepsy syndrome) Lennox-Gastaut syndrome or epilepsy of unknown origin. [11] However, the disorder has a distinct evolution of symptoms, and is associated with specific genetic mutations of the PCDH19 gene. [11]

Seizures

The hallmark characteristic of PCDH19 gene-related epilepsy is early-onset cluster seizures that often cause cyanotic spells, which start in infancy or early childhood. [4] [5] [6] [7] The onset of the first cluster of seizures usually coincides with a fever (febrile seizures), however subsequent seizures may be febrile or afebrile. [4] [5] [17] The seizure clusters are generally brief seizures, lasting 1–5 minutes, often accompanied by fearful screaming observed in 63% of girls. [4] [5] [11] [15] [17] [18] [ excessive citations ] These cluster seizures can occur more than 10 times a day over several days, with varying amounts of time between seizure clusters. [4] [11]

Over time, children with PCDH19 gene-related epilepsy tend to exhibit multiple seizure types, including focal, generalized tonic-clonic, tonic, atonic, myoclonus, and absence seizures. [15] [16] In a small study of 35 female patients with PCDH19 gene-related epilepsy, rare episodes of status epilepticus occurred in about 30% of patients in the early course of the disorder. [18]

In PCDH19 gene-related epilepsy, the seizures are often refractory to treatment, especially in infancy and childhood. [11] [12] [18] Additionally, seizures are usually characterized by persistence of cluster seizures, with variable frequency. [11] [18] In a study of 35 female patients with PCDH19 gene-related epilepsy, approximately 30% had become seizure free in the girl's childhood (mean age of 12 years), yet some continued into adulthood. [18] In the same study, a few patients still had recurrent cluster seizures that evolved into status epilepticus in childhood or early adolescence. [18]

Developmental problems

Beyond early-onset and treatment-resistant cluster seizures, PCDH19 gene-related epilepsy is usually, but not always, associated with cognitive and sensory impairment of varying degrees, and psychiatric and behavioral problems. [4] [5] [6] [7] [11] [12] [13] [14] [15] [ excessive citations ] It is estimated that up to 60 to 75% of the females have cognitive deficits, ranging from mild to severe intellectual disability, which do not appear to be related to frequency or severity of seizures. [6] [7] [11] [12] [13] [14] Development over the course of a female patients' childhood can follow one of three courses: delays from birth that persist into adulthood, normal development and then regression, or normal intellectual development. [6] [11] It is not yet clear why some people experience delayed intellectual growth and others regress with epilepsy. [14] [19]

From the University of Melbourne study, two-thirds of PCDH19 gene-related epilepsy patients have borderline intellectual functioning or intellectual disability, while one third have normal intelligence. [14] A connection to depression, autism, obsessive and aggressive behaviors and other disorders has been observed in PCDH19 gene-related epilepsy. [4] [5] [6] [7] [11] [12] [13] [14] [ excessive citations ] Approximately 40-60% of girls diagnosed with a PCDH19 mutation are on the autism spectrum. [6] [13] [14] [17]

Many of those with PCDH19 gene mutations also exhibit behavioral and psychological problems – including ADHD, aggression, obsessive-compulsive disorder, and anxiety. [6] [13] [14] [17] Other neurological abnormalities may present, including sleep disturbances, ictal apnea, motor deficits, hypotonia, language delay, sensory integration problems and dysautonomia. [6]

Causes

A 2008 study found a relationship between the PCDH19 gene and early onset female seizures, with subsequent studies confirming the relationship. [14] [15] [19] [20]

PCDH19 gene-related epilepsy can arise as a single case in a family, due to a de novo error in cell replication, or it can be inherited. [11] [12] [13] In a large series of cases in which inheritance was determined, half of the PCDH19 mutations occurred de novo, and half were inherited from fathers in good health, and who had no evidence of seizures or cognitive disorders. [11] [12] [13]

Men and women can transmit the PCDH19 mutation, although females, but not males, usually, but not always, exhibit symptoms, which can be very mild. Females with a mutation have a 50% chance of having children who are carriers. Men have a 100% chance of transmitting the mutation to a daughter and 0% chance to a son. [11] [12] [13] [14]

Although males do not generally exhibit PCDH19 gene-related history such as cluster seizures, in a study involving four families with PCDH19 gene mutations, 5 of the fathers had obsessive and controlling tendencies. [14] The linkage of chromosome Xq22.1 to PCDH19 gene-related epilepsy in females was confirmed in all of the families. [14]

The inheritance pattern is very unusual, in that men that carry the PCDH19 gene mutation on their only X-chromosome are typically unaffected, except in rare instances of somatic mosaicism.[11] [11] Alternatively, approximately 90% of women, who have the mutation on one of their two X-chromosomes, exhibit symptoms. [11] [12] [13] It has been suggested that the greater occurrence of PCDH19-epilepsy in females may relate to X-chromosome inactivation, through a hypothesized mechanism termed cellular interference. [5] [11]

A 2011 study found instances where patients had PCDH19 mutation, but their parents did not. They found that "gonadal mosaicism" of a PCDH19 mutation in a parent is an important molecular mechanism associated with the inheritance of a mutated PCDH19 gene. [5] [11] [21]

Genetics

The PCDH19 gene is located on the long (q) arm of the X chromosome at position 22.1. [4] [9] [12] [15] The gene encodes for protocadherin 19, a transmembrane protein of calcium-dependent cell-cell adhesion molecules that is strongly expressed in neural tissue, such as the hippocampus, cerebral cortex, thalamus, and amygdala. [11] [12] [15] Protocadherin 19 appears to be related to synaptic transmission and formation of synaptic connections during brain development. [12] [15]

A mutation in the PCDH19 gene can cause the protocadherin 19 protein to be malformed, reduced in function or not produced at all. [12] This abnormal expression of protocadherin 19 causes deficits in GABAergic signaling, causing the occurrence of seizures beginning in the early years of life. [12]

The expression of the PCDH19 mutation is highly variable, with some individuals appearing unaffected, and others showing severe disease. [5] Even monozygotic twins with the mutation may have variations in seizure frequency and degree of cognitive impairment. [5]

Currently, the PCDH19 gene is the second most clinically relevant gene in the epilepsy field; the second largest number of epilepsy related mutations characterized thus far occur in the PCDH19 gene. [4] [5] [15] [17] The SCN1A gene, associated with Dravet syndrome, is the most clinically relevant. [22] [23]

Diagnosis

PCDH19 gene-related epilepsy is clinically based on patient and family seizure history, cognitive and behavioral neuropsychological evaluation, neurological examination, electroencephalogram (EEG) studies, and long term observation. Diagnosis is confirmed using molecular testing for PCDH19 mutations. [17] [22]

Diagnostic test

The test is particularly indicated in children who have had cluster seizures in series. It is also recommended for patients who are diagnosed GEFS+ and when the seizures are associated with fever, infection, experienced regression, delayed cognitive growth or behavioral problems. The test is typically ordered by neurologists. The diagnostic test can be done by drawing blood or saliva of the patient and their immediate family. It is analyzed in laboratories that specialize in genetic testing. Genetic testing can aid in a firmer diagnosis and understanding of the disorder, may aid in identifying the optimal treatment plan and if positive, testing of the parents can determine if they are carriers. [ citation needed ]

Classification

Due to its recent discovery, PCDH19 gene-related epilepsy does not have a specific classification according to the International League Against Epilepsy.

PCDH19 gene-related epilepsy is thought to develop based upon a deficiency of the calcium-dependent cell-adhesion PCDH19 (protocadherin 19) gene. [24] [nb 1] Its cause and pathophysiology (cause and mechanisms by which damage occurs) are different from other epilepsies, although the symptoms are very similar to other epileptic syndromes, such as Generalized epilepsy with febrile seizures plus (GEFS+), Dravet syndrome with SCN1A negative, FIRES (febrile infection–related epilepsy syndrome) Lennox-Gastaut syndrome or epilepsy of unknown origin. [25]

Treatment

Medication

Antiepileptic drugs (AEDs) are used in most cases to control seizures, however, PCDH19 gene-related epilepsy is generally associated with early-onset development of drug resistant seizures. [9] [11] [16] Existing data supports the use of "rational polypharmacy," which consists of a step-wise addition of AEDs until a patient responds favorably or experiences intolerable adverse events. [9] In general, as in other types of uncontrolled epilepsy, the use of drugs with different mechanisms of action appears to be more effective than combining drugs with similar mechanisms of action. [9]

No currently marketed AEDs have been extensively studied in PCDH19 gene-related epilepsy and there is no established treatment strategy for girls diagnosed with PCDH19 gene-related epilepsy. [16] [22] Patients may respond well to treatment with levetiracetam and in cases of drug resistance, stiripentol, which is not approved in the U.S. but is available through the FDA Expanded Access IND process. [5] [22] Seizures might be easier to control with age, especially after the second decade of life. However, some publications have shown that medication withdrawal is highly associated with seizure recurrence. [26]

Urgent care

At the hospital, physicians follow standard protocol for managing seizures. Cluster seizures are generally controlled by benzodiazepines such as diazepam, midazolam, lorazepam or clonazepam. The use of oxygen is recommended in the United States, but in Europe it is only recommended in cases of prolonged epileptic status. [27]

Epidemiology

According to data collected by 2020, PCDH19 (orange) was among the six genes most involved in genetic epilepsies. From a review by Giovanni Battista Dell'Isola et al., 2021. Prevalence of different gene mutations in genetic epilepsies according to literature data by year 2020.jpg
According to data collected by 2020, PCDH19 (orange) was among the six genes most involved in genetic epilepsies. From a review by Giovanni Battista Dell'Isola et al., 2021.

The National Institute of Health Office and Rare Disease Research characterizes PCDH19 gene-related epilepsy as a rare disorder. [8] Rare diseases, by definition, are diseases that affect fewer than 200,000 people in the United States. Since the mutation associated with PCDH19 gene-related epilepsy was only recently identified in 2008, the true incidence of the disease is generally unknown. [12]

Although formal epidemiologic data is not available, results from diagnostic screening indicates that approximately 1 out of 10 girls who have seizure onset before five years of age may have PCDH19 gene mutations. [9] [10] [11] Additionally, PCDH19 screening of several large cohorts of females with early onset febrile-related epilepsy has resulted in a rate of approximately 10% of mutation-positive individuals. [11] [17] [22]

History

Juberg and Hellman originally described the disorder in 1971 in the Journal of Pediatrics , where they reported a family in which 15 female relatives, who were related either as sisters or first cousins through their fathers, had early onset seizures with cognitive impairments. [4] [8] [16] In subsequent peer-reviewed literature, the disorder was referred to as "epilepsy and mental retardation limited to female" (EFMR), and later called EIEE9 or Juberg-Hellman syndrome. [4] [8] [12] The syndrome in this family was characterized by the occurrence of childhood seizures. Some of the girls showed developmental regression with intellectual disabilities that ranged from mild to profound. The disorder has an unusual inheritance pattern. It is considered X-linked dominant with male carriers. Women and men with the affected gene can transmit the disease. The men expressed a normal phenotype. The disorder was shown to be linked to mutations via Xq22 microsatellite markers.[nb 4] [4]

Due to the apparent female-limited expression of the condition, it eluded genetic mapping until 1997, which is when Ryan et al. mapped the responsible gene to the X-chromosome. [29]

Eleven years after the success of Ryan et al., in 2008, systematic sequencing of X-chromosome exons in seven large families diagnosed with EFMR revealed PCDH19 gene mutations as the cause. This led to a shift in describing EMFR as PCDH19 gene-related epilepsy. [9] [13] [14] [17] [29] The discovery of the PCDH19 gene mutation led to the development of a genetic test for PCDH19 gene-related epilepsy.[ citation needed ]

In 2009, Depienne et al. identified a male with a somatic mosaicism for PCDH19 gene deletion and a Dravet-like seizure disorder. [9] [11] [29] [30] [31] The findings resulted in Depienne et al. to identify PCDH19 mutations in patients with SCN1A negative Dravet syndrome. [9] [11] [29] This led to additional reports of PCDH19 positive patients, which broadened the clinical spectrum of the disorder. [29] [30] [31]

Society and culture

Caregivers of individuals living with PCDH19 gene-related epilepsy may seek support and information from a variety of resources, including the PCDH19 Alliance, the Cute Syndrome Foundation, and Insieme per la Ricerca PCDH19 - ONLUS (Italy).[ citation needed ]

The PCDH19 World Conference, which is organized by Insieme per la Ricerca PCDH19 - ONLUS, occurs every other year, in odd years, in Rome, Italy. In alternating years, the PCDH19 Epilepsy Professional and Family Symposium is hosted in San Francisco, California.[ citation needed ]

In 2014, the PCDH19 Registry was established, which is organized and funded by the PCHD19 Alliance, Boston Children's Hospital and the University of California, San Francisco. [6] International PCDH19 Awareness Day is held annually on November 9.[ citation needed ]

Research

Registry

A PCDH19 Registry was established by the PCDH19 Alliance, Boston Children's Hospital and the University of California, San Francisco, to provide a meaningful resource of patients with PCDH19 gene-related epilepsy and to better understand the epilepsy and behavioral aspects associated with the mutation. [6] [32]

Parallel associations European families are sponsoring basic and applied research in an Australian team and researching in other projects with the aim of finding a drug target for epilepsy PCDH19.[28]

Basic research

Ann Poduri and Alex Rotenberg at Boston Children's Hospital are currently conducting PCDH19-related epilepsy in zebrafish. [32] [33] The research, which is funded by grants from the Cute Syndrome Foundation and The Richard A. and Susan F. Smith President's Innovation Fund of Boston Children's Hospital, hopes to establish an animal model of PCDH19 gene-related epilepsy, which can then be used to screen potential therapeutics and treatments. [32] [33]

Dr. Jack Parent and his research team at the University of Michigan are currently conducting research to understand how PCHD19 gene mutations leads to disruptions in brain development. [34] [35] The research, funded by a grant from the Cute Syndrome Foundation, is seeking to reprogram fibroblasts from subjects with the PCHD19 mutation into induced pluripotent stem cells (iPSC), which will then be used to make patient-specific neurons in a cell culture environment. [34] [35] The researchers are looking to see if these patient-specific neurons produce epileptic-like activity, as well as to discover the mechanism underlying the seizures and cognitive dysfunction associated with PCDH19 mutations. [34] [35]

The Cute Syndrome Foundation and Insieme per la Ricerca PCDH19 - ONLUS recently awarded a two-year research grant to Drs. Maria Passafaro and Elena Battaglioli, from the CNR Neuroscience Institute and University of Milano, respectively. [35] [36] The researchers plan to unravel the molecular mechanism of PCDH19 gene mutations. [35] [36] The proposal also includes using AON exon skipping, which would be the first use of this method in epilepsy. [35] [36]

Parallel associations European families are sponsoring basic and applied research in an Australian team and researching in other projects with the aim of finding a drug target for epilepsy PCDH19. [37] [ clarification needed ]

Gene therapy

It was assumed that all encephalopathies or cognitive impairments were irreversible, but an experiment with mice showed that is not always the case. [38] In that experiment, MECP2 protein was blocked; males died, and females developed Rett syndrome (seizures, cognitive and psychomotor problems, respiratory problems, etc.) When the researchers reversed the situation and let the MECP2 protein work properly, the mice recovered.[ clarification needed ] This research revolutionized understanding regarding genetic syndromes that present with neurological impairment or intellectual disabilities.[ citation needed ]

Therapeutics

In February 2015, Marinus Pharmaceuticals commenced a Phase 2 proof-of-concept clinical trial to evaluate the safety and efficacy of ganaxolone, a synthetic analog of the neurosteroid allopregnanolone, for the treatment of uncontrolled seizure in pediatric females with PCDH19 gene-related epilepsy. [39] [40] The study will enroll up to 10 female pediatric patients, between the ages of 2 and 10 years old, with a confirmed PCDH19 genetic mutation. [34] [35] [40] The primary endpoint of the study is percent change in seizure frequency per 28 days relative to baseline. [39] [40]

The Epilepsies Research Centre and Department of Medicine, University of Melbourne, are working on a compound to treat this disease. On May 26, 2011, it patented a method of diagnosis and PCDH19 gene-related epilepsy treatment. [41]

Notes

  1. ↑ Cell adhesion is mediated by cell surface proteins.

Related Research Articles

<span class="mw-page-title-main">Epilepsy</span> Group of neurological disorders causing seizures

Epilepsy is a group of non-communicable neurological disorders characterized by recurrent epileptic seizures. An epileptic seizure is the clinical manifestation of an abnormal, excessive, and synchronized electrical discharge in the brain cells called neurons. The occurrence of two or more unprovoked seizures defines epilepsy. The occurrence of just one seizure may warrant the definition in a more clinical usage where recurrence may be able to be prejudged. Epileptic seizures can vary from brief and nearly undetectable periods to long periods of vigorous shaking due to abnormal electrical activity in the brain. These episodes can result in physical injuries, either directly such as broken bones or through causing accidents. In epilepsy, seizures tend to recur and may have no immediate underlying cause. Isolated seizures that are provoked by a specific cause such as poisoning are not deemed to represent epilepsy. People with epilepsy may be treated differently in various areas of the world and experience varying degrees of social stigma due to the alarming nature of their symptoms.

<span class="mw-page-title-main">Lennox–Gastaut syndrome</span> Rare form of childhood-onset epilepsy

Lennox–Gastaut syndrome (LGS) is a complex, rare, and severe childhood-onset epilepsy syndrome. It is characterized by multiple and concurrent seizure types including tonic seizure, cognitive dysfunction, and slow spike waves on electroencephalogram (EEG), which are very abnormal. Typically, it presents in children aged 3–5 years and most of the time persists into adulthood with slight changes in the electroclinical phenotype. It has been associated with perinatal injuries, congenital infections, brain malformations, brain tumors, genetic disorders such as tuberous sclerosis and numerous gene mutations. Sometimes LGS is observed after infantile epileptic spasm syndrome. The prognosis for LGS is marked by a 5% mortality in childhood and persistent seizures into adulthood.

Generalized epilepsy with febrile seizures plus (GEFS+) is a syndromic autosomal dominant disorder where affected individuals can exhibit numerous epilepsy phenotypes. GEFS+ can persist beyond early childhood. GEFS+ is also now believed to encompass three other epilepsy disorders: severe myoclonic epilepsy of infancy (SMEI), which is also known as Dravet's syndrome, borderline SMEI (SMEB), and intractable epilepsy of childhood (IEC). There are at least six types of GEFS+, delineated by their causative gene. Known causative gene mutations are in the sodium channel α subunit genes SCN1A, an associated β subunit SCN1B, and in a GABAA receptor γ subunit gene, in GABRG2 and there is another gene related with calcium channel the PCDH19 which is also known as Epilepsy Female with Mental Retardation. Penetrance for this disorder is estimated at 60%.

Dravet syndrome (DS), previously known as severe myoclonic epilepsy of infancy (SMEI), is an autosomal dominant genetic disorder which causes a catastrophic form of epilepsy, with prolonged seizures that are often triggered by hot temperatures or fever. It is very difficult to treat with anticonvulsant medications. It often begins before one year of age, with six months being the age that seizures, char­ac­ter­ized by prolonged convulsions and triggered by fever, usually begin.

Childhood absence epilepsy (CAE), formerly known as pyknolepsy, is an idiopathic generalized epilepsy which occurs in otherwise normal children. The age of onset is between 4–10 years with peak age between 5–7 years. Children have absence seizures which although brief, they occur frequently, sometimes in the hundreds per day. The absence seizures of CAE involve abrupt and severe impairment of consciousness. Mild automatisms are frequent, but major motor involvement early in the course excludes this diagnosis. The EEG demonstrates characteristic "typical 3Hz spike-wave" discharges. The presence of any other seizure type at time of diagnosis rules out the diagnose of CAE. Prognosis is usually good in well-defined cases of CAE with most patients "growing out" of their epilepsy.

Idiopathic generalized epilepsy (IGE) is a group of epileptic disorders that are believed to have a strong underlying genetic basis. IGE is considered a subgroup of Genetic Generalized Epilepsy (GGE). Patients with an IGE subtype are typically otherwise normal and have no structural brain abnormalities. People also often have a family history of epilepsy and seem to have a genetically predisposed risk of seizures. IGE tends to manifest itself between early childhood and adolescence although it can be eventually diagnosed later. The genetic cause of some IGE types is known, though inheritance does not always follow a simple monogenic mechanism.

<span class="mw-page-title-main">CDKL5</span> Protein-coding gene in humans

CDKL5 is a gene that provides instructions for making a protein called cyclin-dependent kinase-like 5 also known as serine/threonine kinase 9 (STK9) that is essential for normal brain development. Mutations in the gene can cause deficiencies in the protein. The gene regulates neuronal morphology through cytoplasmic signaling and controlling gene expression. The CDKL5 protein acts as a kinase, which is an enzyme that changes the activity of other proteins by adding a cluster of oxygen and phosphorus atoms at specific positions. Researchers are currently working to determine which proteins are targeted by the CDKL5 protein.

Progressive Myoclonic Epilepsies (PME) are a rare group of inherited neurodegenerative diseases characterized by myoclonus, resistance to treatment, and neurological deterioration. The cause of PME depends largely on the type of PME. Most PMEs are caused by autosomal dominant or recessive and mitochondrial mutations. The location of the mutation also affects the inheritance and treatment of PME. Diagnosing PME is difficult due to their genetic heterogeneity and the lack of a genetic mutation identified in some patients. The prognosis depends largely on the worsening symptoms and failure to respond to treatment. There is no current cure for PME and treatment focuses on managing myoclonus and seizures through antiepileptic medication (AED).

Ohtahara syndrome (OS), also known as early infantile epileptic encephalopathy (EIEE) is a progressive epileptic encephalopathy. The syndrome is outwardly characterized by tonic spasms and partial seizures within the first few months of life, and receives its more elaborate name from the pattern of burst activity on an electroencephalogram (EEG). It is an extremely debilitating progressive neurological disorder, involving intractable seizures and severe intellectual disabilities. No single cause has been identified, although in many cases structural brain damage is present.

SCN1A Protein-coding gene in the species Homo sapiens

Sodium channel protein type 1 subunit alpha (SCN1A), is a protein which in humans is encoded by the SCN1A gene.

<span class="mw-page-title-main">Spike-and-wave</span>

Spike-and-wave is a pattern of the electroencephalogram (EEG) typically observed during epileptic seizures. A spike-and-wave discharge is a regular, symmetrical, generalized EEG pattern seen particularly during absence epilepsy, also known as ‘petit mal’ epilepsy. The basic mechanisms underlying these patterns are complex and involve part of the cerebral cortex, the thalamocortical network, and intrinsic neuronal mechanisms.

<span class="mw-page-title-main">Rolandic epilepsy</span> Most common epilepsy syndrome in childhood, usually subsiding with age

Benign Rolandic epilepsy or self-limited epilepsy with centrotemporal spikes is the most common epilepsy syndrome in childhood. Most children will outgrow the syndrome, hence the label benign. The seizures, sometimes referred to as sylvian seizures, start around the central sulcus of the brain.

Early myoclonic encephalopathy (EME) is a rare neonatal-onset epilepsy developmental and epileptic encephalopathy (DEE) with an onset at neonatal period or during the first 3 months of life. This syndrome is now included as part of the Early infantile developmental and epileptic encephalopathy (EIDEE) under the 2022 ILAE syndrome classification.

Febrile infection-related epilepsy syndrome (FIRES), is onset of severe seizures following a febrile illness in someone who was previously healthy. The seizures may initially be focal; however, often become tonic-clonic. Complications often include intellectual disability, behavioral problems, and ongoing seizures.

People with epilepsy may be classified into different syndromes based on specific clinical features. These features include the age at which seizures begin, the seizure types, and EEG findings, among others. Identifying an epilepsy syndrome is useful as it helps determine the underlying causes as well as deciding what anti-seizure medication should be tried. Epilepsy syndromes are more commonly diagnosed in infants and children. Some examples of epilepsy syndromes include benign rolandic epilepsy, childhood absence epilepsy and juvenile myoclonic epilepsy. Severe syndromes with diffuse brain dysfunction caused, at least partly, by some aspect of epilepsy, are also referred to as epileptic encephalopathies. These are associated with frequent seizures that are resistant to treatment and severe cognitive dysfunction, for instance Lennox-Gastaut syndrome and West syndrome.

Lori L. Isom is an American pharmacologist, an elected Fellow of the American Association for the Advancement of Science, and a member of the National Academy of Medicine.

SYNGAP1-related intellectual disability is a monogenetic developmental and epileptic encephalopathy that affects the central nervous system. Symptoms include intellectual disability, epilepsy, autism, sensory processing deficits, hypotonia and unstable gait.

CDKL5 deficiency disorder (CDD) is a rare genetic disorder caused by pathogenic variants in the gene CDKL5.

Malignant migrating partial seizures of infancy (MMPSI) is a rare epileptic syndrome that onsets before 6 months of age, commonly in the first few weeks of life. Once seizures start, the site of seizure activity repeatedly migrates from one area of the brain to another, with few periods of remission in between. These seizures are 'focal' (updated term for 'partial'), meaning they do not affect both sides of the brain at the same time. These continuous seizures cause damage to the brain, hence the descriptor 'malignant.'

SLC6A1 epileptic encephalopathy is a genetic disorder characterised by the loss-of-function of one copy of the human SLC6A1 gene. SLC6A1 epileptic encephalopathy can typically manifest itself with early onset seizures and it can also be characterised by mild to severe learning disability. Not all manifestations of the conditions are present in one given patient.

References

  1. 1 2 Stevenson RE, Holden KR, Rogers RC, Schwartz CE (May 2012). "Seizures and X-linked intellectual disability". European Journal of Medical Genetics . 55 (5): 307–12. doi:10.1016/j.ejmg.2012.01.017. PMC   3531238 . PMID   22377486.
  2. ↑ Carol Perez-Iratxeta; Peer Bork; Miguel A. Andrade. "Genes2Diseases database". Archived from the original on 2013-12-02. Retrieved 2013-11-22.
  3. ↑ "Entry – #300088 – Developmental and Epileptic Encephalopathy 9; DEE9 – OMIM". omim.org.
  4. 1 2 3 4 5 6 7 8 9 10 11 12 13 Depienne, C; LeGeurn, E (2012). "PCDH19-related infantile epileptic encephalopathy: an unusual X-linked inheritance disorder". Human Mutation. 33 (4): 627–634. doi:10.1002/humu.22029. PMID   22267240. S2CID   40463330.
  5. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 Higurashi, N.; Nakamura, M.; Sugai, M.; Ohfu, M.; Sakauchi, M.; Sugawara, Y.; Nakamura, K.; Kato, M.; Usui, D.; Mogami, Y.; Fujiwara, Y.; Ito, T.; Ikeda, H.; Imai, K.; Takahashi, Y.; Nukui, M.; Inoue, T.; Okazaki, S.; Kirino, T.; Tomonoh, Y.; Inoue, T.; Takano, K.; Shimakawa, S.; Hirose, S. (2013). "PCDH19-related female-limited epilepsy: Further details regarding early clinical features and therapeutic efficacy". Epilepsy Research. 106 (1–2): 191–199. doi:10.1016/j.eplepsyres.2013.04.005. PMID   23712037. S2CID   20561773.
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 "PCDH19 Alliance" . Retrieved August 22, 2016.
  7. 1 2 3 4 5 6 7 Specchio, N; Marini, C; Terracciano, A (2011). "Spectrum of phenotypes in female patients with epilepsy due to protocadherin 19 mutations". Epilepsia. 52 (7): 1251–1257. doi: 10.1111/j.1528-1167.2011.03063.x . PMID   21480887.
  8. 1 2 3 4 "PCDH19-related female-limited epilepsy | Genetic and Rare Diseases Information Center(GARD) – an NCATS Program". rarediseases.info.nih.gov. Retrieved 2016-08-22.
  9. 1 2 3 4 5 6 7 8 9 Depienne, Christel; Bouteiller, Delphine; Keren, Boris; Cheuret, Emmanuel; Poirier, Karine; Trouillard, Oriane; Benyahia, Baya; Quelin, Chloé; Carpentier, Wassila (2009-02-13). "Sporadic Infantile Epileptic Encephalopathy Caused by Mutations in PCDH19 Resembles Dravet Syndrome but Mainly Affects Females". PLOS Genet. 5 (2): e1000381. doi: 10.1371/journal.pgen.1000381 . ISSN   1553-7404. PMC   2633044 . PMID   19214208.
  10. 1 2 Depienne C, Trouillard O, Bouteiller D, Gourfinkel-An I, Poirier K, Rivier F, et al. (January 2011). "Mutations and deletions in PCDH19 account for various familial or isolated epilepsies in females". Human Mutation. 32 (1): E1959–75. doi:10.1002/humu.21373. PMC   3033517 . PMID   21053371.
  11. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Johnston, Michael (2016). Neurobiology of Disease. Oxford University Press. pp. 307–309. ISBN   978-0199937844.
  12. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Dibbens, LM; Tarpey, PS (June 2008). "X-linked protocadherin 19 mutations cause female-limited epilepsy and cognitive impairment". Nature Genetics. 40 (6): 776–781. doi:10.1038/ng.149. PMC   2756413 . PMID   18469813.
  13. 1 2 3 4 5 6 7 8 9 10 11 Depienne, Christel; Gourfinkel-An, Isabelle; Baulac, Stéphanie; LeGuern, Eric (2012-01-01). Noebels, Jeffrey L.; Avoli, Massimo; Rogawski, Michael A.; Olsen, Richard W.; Delgado-Escueta, Antonio V. (eds.). Genes in infantile epileptic encephalopathies (4th ed.). Bethesda (MD): National Center for Biotechnology Information (US). PMID   22787626.
  14. 1 2 3 4 5 6 7 8 9 10 11 12 13 Scheffer, Ingrid; et al. (2008). "Epilepsy and mental retardation limited to females: an under-recognized disorder". Brain. 131 (4): 918–927. doi: 10.1093/brain/awm338 . PMID   18234694.
  15. 1 2 3 4 5 6 7 8 9 Cappelletti, Simona; Specchio, Nicola; Moavero, Romina; Terracciano, Alessandra; Trivisano, Marina; Pontrelli, Giuseppe; Gentile, Simonetta; Vigevano, Federico; Cusmai, Raffaella (2015). "Cognitive development in females with PCDH19 gene-related epilepsy". Epilepsy & Behavior. 42: 36–40. doi:10.1016/j.yebeh.2014.10.019. PMID   25499160. S2CID   13227576.
  16. 1 2 3 4 5 Nordli Jr., Douglas (2016). Pellock's Pediatric Epilepsy: Diagnosis and Therapy. Springer Publishing Company. p. 386. ISBN   978-1617052439.
  17. 1 2 3 4 5 6 7 8 Marini C, Mei D, Parmeggiani L, Norci V, Calado E, Ferrari A, Moreira A, Pisano T, Specchio N, Vigevano F, Battaglia D, Guerrini R (August 2010). "Protocadherin 19 mutations in girls with infantile-onset epilepsy". Neurology. 75 (7): 646–53. doi:10.1212/WNL.0b013e3181ed9e67. PMID   20713952. S2CID   40368257.
  18. 1 2 3 4 5 6 Marini C, Darra F, Specchio N, Mei D, Terracciano A, Parmeggiani L, et al. (December 2012). "Focal seizures with affective symptoms are a major feature of PCDH19 gene-related epilepsy". Epilepsia. 53 (12): 2111–9. doi:10.1111/j.1528-1167.2012.03649.x. hdl: 11365/1000813 . ISSN   1528-1167. PMID   22946748. S2CID   8071244.
  19. 1 2 Marini C.; et al. (June 29, 2010). Infantile onset focal epilepsy and epilepetic encephalopathies associated with PCDH19 gene mutations: New de novo and familial mutations. 9th European Congress on Epileptology. Vol. 51. pp. 1–189. doi:10.1111/j.1528-1167.2010.02658.x. hdl: 11446/404 . PMID   20590792.
  20. ↑ Specchio, N (2011-08-01). "Stormy Onset Epilepsy in Girls with De Novo Protocadherin 19 Mutations". Epilepsia. 52: 4–22. doi: 10.1111/j.1528-1167.2011.03206.x . ISSN   1528-1167.
  21. ↑ Dibbens, L. M.; Kneen, R.; Bayly, M. A.; Heron, S. E.; Arsov, T.; Damiano, J. A.; Desai, T.; Gibbs, J.; McKenzie, F. (2011-04-26). "Recurrence risk of epilepsy and mental retardation in females due to parental mosaicism of PCDH19 mutations". Neurology. 76 (17): 1514–1519. doi:10.1212/WNL.0b013e318217e7b6. ISSN   0028-3878. PMID   21519002. S2CID   25105085.
  22. 1 2 3 4 5 Miller, Ian O.; Sotero de Menezes, Marcio A. (1993-01-01). "SCN1A Seizure Disorders". In Pagon, Roberta A.; Adam, Margaret P.; Ardinger, Holly H.; Wallace, Stephanie E.; Amemiya, Anne; Bean, Lora J.H.; Bird, Thomas D.; Fong, Chin-To; Mefford, Heather C. (eds.). SCN1A-Related Seizure Disorders. Seattle (WA): University of Washington, Seattle. PMID   20301494.
  23. ↑ Sugawara, Takashi; Tsurubuchi, Yuji; Agarwala, Kishan Lal; Ito, Masatoshi; Fukuma, Goryu; Mazaki-Miyazaki, Emi; Nagafuji, Hiroshi; Noda, Masaharu; Imoto, Keiji (2001-05-22). "A missense mutation of the Na+ channel αII subunit gene Nav1.2 in a patient with febrile and afebrile seizures causes channel dysfunction". Proceedings of the National Academy of Sciences. 98 (11): 6384–6389. Bibcode:2001PNAS...98.6384S. doi: 10.1073/pnas.111065098 . ISSN   0027-8424. PMC   33477 . PMID   11371648.
  24. ↑ "PCDH19 Gene". Genetic Home Reference. Archived from the original on July 5, 2013. Retrieved December 30, 2011.
  25. ↑ Nicola Specchio; Lucia Fusco; Federico Vigevano (November 2011). "Acute-onset epilepsy triggered by fever mimicking FIRES febrile infection–related epilepsy syndrome: The role of protocadherin 19 (PCDH19) gene mutation". Epilepsia. 52 (11): e172–e175. doi: 10.1111/j.1528-1167.2011.03193.x . PMID   21777234. S2CID   35858941.
  26. ↑ Aledo-Serrano, Ángel; Ser, Teodoro del; Gil-Nagel, Antonio (2020-06-05). "Antiseizure medication withdrawal in seizure-free patients with PCDH19-related epilepsy: a multinational cohort survey". Seizure: European Journal of Epilepsy. 80: 259–261. doi: 10.1016/j.seizure.2020.06.007 . ISSN   1059-1311. PMID   32682289. S2CID   219559784.
  27. ↑ "The Epilepsies and Seizures: Hope Through Research". www.ninds.nih.gov. Archived from the original on 2016-07-27. Retrieved 2016-08-22.
  28. ↑ Dell'Isola GB, Vinti V, Fattorusso A, Tascini G, Mencaroni E, Di Cara G, Striano P, Verrotti A (2021). "The Broad Clinical Spectrum of Epilepsies Associated With Protocadherin 19 Gene Mutation". Frontiers in Neurology. 12: 780053. doi: 10.3389/fneur.2021.780053 . PMC   8801579 . PMID   35111125.
  29. 1 2 3 4 5 Tan, Chuan; Shard, Chloe; Ranieri, Enzo; Hynes, Kim; Pham, Duyen H.; Leach, Damian; Buchanan, Grant; Corbett, Mark; Shoubridge, Cheryl (2015-09-15). "Mutations of protocadherin 19 in female epilepsy (PCDH19-FE) lead to allopregnanolone deficiency". Human Molecular Genetics. 24 (18): 5250–5259. doi: 10.1093/hmg/ddv245 . ISSN   0964-6906. PMID   26123493.
  30. 1 2 Terracciano, Alessandra; Trivisano, Marina; Cusmai, Raffaella; De Palma, Luca; Fusco, Lucia; Compagnucci, Claudia; Bertini, Enrico; Vigevano, Federico; Specchio, Nicola (2016-03-01). "PCDH19-related epilepsy in two mosaic male patients". Epilepsia. 57 (3): e51–e55. doi: 10.1111/epi.13295 . ISSN   1528-1167. PMID   26765483.
  31. 1 2 Thiffault, Isabelle; Farrow, Emily; Smith, Laurie; Lowry, Jennifer; Zellmer, Lee; Black, Benjamin; Abdelmoity, Ahmed; Miller, Neil; Soden, Sarah (2016-06-01). "PCDH19-related epileptic encephalopathy in a male mosaic for a truncating variant". American Journal of Medical Genetics Part A. 170 (6): 1585–1589. doi:10.1002/ajmg.a.37617. ISSN   1552-4833. PMID   27016041. S2CID   36753614.
  32. 1 2 3 "Epilepsy Genetics Program | Research and Innovation". www.childrenshospital.org. Retrieved 2016-08-22.
  33. 1 2 "PCDH19 and SCN8A Research Funded By The Cute Syndrome". The Cute Syndrome Foundation: Funding PCDH19 Epilepsy &
    SCN8A Epilepsy Research    . Retrieved 2016-08-22.
  34. 1 2 3 4 "Research - PCDH19 Alliance". PCDH19 Alliance. Retrieved 2016-08-22.
  35. 1 2 3 4 5 6 7 "News about PCDH19 Epilepsy and SCN8A Epilepsy and The Cute Syndrome Foundation". The Cute Syndrome Foundation: Funding PCDH19 Epilepsy &
    SCN8A Epilepsy Research    . Retrieved 2016-08-22.
  36. 1 2 3 "Insieme per la Ricerca PCDH19 – ONLUS". www.pcdh19research.org. Archived from the original on 2016-07-26. Retrieved 2016-08-22.
  37. ↑ PCDH19 Association "Insieme per la Ricerca PCDH19"
  38. ↑ Guy, Jacky; Gan, Jian; Selfridge, Jim; Cobb, Stuart; Bird, Adrian (2007-02-23). "Reversal of Neurological Defects in a Mouse Model of Rett Syndrome". Science. 315 (5815): 1143–1147. Bibcode:2007Sci...315.1143G. doi:10.1126/science.1138389. ISSN   0036-8075. PMC   7610836 . PMID   17289941.
  39. 1 2 "Marinus Pharmaceuticals Initiates Clinical Trial With Ganaxolone in PCDH19 Female Pediatric Epilepsy (NASDAQ:MRNS)". ir.marinuspharma.com. Retrieved 2016-08-22.
  40. 1 2 3 "A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children With PCDH19 Female Pediatric Epilepsy - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 2016-08-22.
  41. ↑ 2011/0126302 A1 USpending US 2011/0126302 A1,Dibbens, L.M.; Scheffer, I.; Berkovic, S.F.; Mulley, J.C.; Geez, J,"Diagnostic and Therapeutic Methods for EFMR (Epilepsy and Mental Retardation",published May 26, 2011
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.